Results 131 to 140 of about 440 (147)

Neurokinin-1 Receptor (NK1R)

2009
openaire   +1 more source

The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration

Neuroscience, 1995
Kenneth E Mccarson, J E Krause, J E Krause   +2 more
exaly  

Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists

Investigational New Drugs, 2018
MIGUEL Munoz, Estefania García-Guerrero, Munoz MIGUEL   +2 more
exaly  

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

Journal of Psychopharmacology, 2013
K Ranga Krishnan, Emiliangelo Ratti, Michael Trower   +2 more
exaly  

Evaluation of constrained amino acids in the design of neurokinin 1 receptor- and bifunctional opioid – neurokinin 1 receptor ligands

Pharmacological Reports, 2011
Steven Ballet, Lukasz Frankiewicz, Karel Guillemyn, Isabelle van den Eynde, Nga N. Chung, Attila Keresztes, Joost Van Duppen, Josephine Lai, Eva Varga, Frank Porreca, Peter W. Schiller, Jozef Vanden Broeck, Dirk Tourwé   +12 more
openaire   +1 more source

Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis

FEBS Letters, 1996
Thue W Schwartz
exaly  

Truncation of neurokinin-1 receptor—Negative regulation of substance P signaling

Journal of Leukocyte Biology, 2018
Sergei Spitsin, Douglas Steven D, Pappa Vasiliki   +2 more
exaly  

Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor

Proceedings of the National Academy of Sciences of the United States of America, 2008
Laurie Kilpatrick, Arti Patel, Douglas Steven D   +2 more
exaly  

Neurokinin 1 Receptor Endocytosis and Signaling

Francisco D. Rodríguez, Rafael Coveñas
openaire   +1 more source

Recent advances in neurokinin-3 receptor antagonists

Expert Opinion on Therapeutic Patents, 2000
exaly